Literature DB >> 6134982

Urothelial dysplasia concomitant with bladder tumours as a determinant factor for future new occurrences.

H Wolf, K Højgaard.   

Abstract

Of 53 patients with primary bladder tumours of categories T1 or T2 about 50% had concomitant urothelial dysplasia, either carcinoma-insitu or less dedifferentiated dysplasia graded as grade II. In a follow-up study of these patients treated with transurethral resection alone, it was found that new occurrences had developed in 87% of patients with concomitant urothelial dysplasia, compared with 26% of those without dysplasia. Most new occurrences developed within 6 months of initial tumour resection. A new invasive tumour developed in all patients with concomitant carcinoma-in-situ, emphasising the serious prognostic significance of that entity. Thus, urothelial dysplasia concomitant with a bladder tumour is an important determinant factor for future new occurrences.

Entities:  

Mesh:

Year:  1983        PMID: 6134982     DOI: 10.1016/s0140-6736(83)90117-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  7 in total

Review 1.  Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

Authors:  O Alfthan; K Jauhiainen; E Kaasinen; T Liukkonen
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

2.  Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?

Authors:  Hanan Goldberg; Douglas C Cheung; Thenappan Chandrasekar; Zachary Klaassen; Christopher J D Wallis; Girish S Kulkarni; Rashid Sayyid; Andrew Evans; Mehdi Masoomian; Bharati Bapat; Theodorus van der Kwast; Robert J Hamilton; Alexandre Zlotta; Neil Fleshner
Journal:  Can Urol Assoc J       Date:  2019-01-21       Impact factor: 1.862

Review 3.  Superficial bladder cancer: state of the art.

Authors:  A V Bono
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Detection of transitional cell carcinoma in bladder by intravesical injection of monoclonal antibodies.

Authors:  D K Chopin; J B deKernion
Journal:  Urol Res       Date:  1986

5.  The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer.

Authors:  L Samodai; L Kiss; Z Kolozsy; L Mohácsi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

6.  Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160.

Authors:  B Szende; E Juhasz; K Lapis; A V Schally
Journal:  Urol Res       Date:  1992

7.  Cytogenetic monoclonality in multifocal uroepithelial carcinomas: evidence of intraluminal tumour seeding.

Authors:  I Fadl-Elmula; L Gorunova; N Mandahl; P Elfving; R Lundgren; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.